Results 1 to 10 of about 39,162 (280)

Quality of care before and after initial certification at a German certified hereditary breast and ovarian cancer center. [PDF]

J Cancer Res Clin Oncol
Genetic mutations contribute to around 10% of breast and 25% of ovarian cancers, with one third of patients having a familial cancer history. The German Consortium for Familial Breast and Ovarian Cancer was founded in 1996 to improve care for these ...
Amann N, Hörner M, Spannring H, Brückner L, Gocke J, Müller C, Boesl C, Bader S, Heindl F, Hack CC, Fasching PA, Beckmann MW, Krückel A.   +12 more
europepmc   +2 more sources

Assessment of Knowledge and Attitude of Breast and Ovarian Cancer Patients Regarding Hereditary Breast-Ovarian Cancer Syndrome at a Tertiary Cancer Institute: A Cross-Sectional Observational Study

Indian Journal of Medical and Paediatric Oncology, 2023
Introduction Hereditary breast and ovarian cancer (HBOC) syndrome affects a significant proportion of our breast and ovarian cancer patients.
Raja Pramanik, Shubhra Vats, Sanchita Mitra, SVS Deo, Lalit Kumar, Ajay Gogia, Sachin Khurana, Atul Batra   +7 more
doaj   +2 more sources

Gene panel testing of 5589 BRCA1/2‐negative index patients with breast cancer in a routine diagnostic setting: results of the German Consortium for Hereditary Breast and Ovarian Cancer

Cancer Medicine, 2018
The prevalence of germ line mutations in non‐BRCA1/2 genes associated with hereditary breast cancer (BC) is low, and the role of some of these genes in BC predisposition and pathogenesis is conflicting.
Jan Hauke, Judit Horvath, Eva Groß, Andrea Gehrig, Ellen Honisch, Karl Hackmann, Gunnar Schmidt, Norbert Arnold, Ulrike Faust, Christian Sutter, Julia Hentschel, Shan Wang‐Gohrke, Mateja Smogavec, Bernhard H. F. Weber, Nana Weber‐Lassalle, Konstantin Weber‐Lassalle, Julika Borde, Corinna Ernst, Janine Altmüller, Alexander E. Volk, Holger Thiele, Verena Hübbel, Peter Nürnberg, Katharina Keupp, Beatrix Versmold, Esther Pohl, Christian Kubisch, Sabine Grill, Victoria Paul, Natalie Herold, Nadine Lichey, Kerstin Rhiem, Nina Ditsch, Christian Ruckert, Barbara Wappenschmidt, Bernd Auber, Andreas Rump, Dieter Niederacher, Thomas Haaf, Juliane Ramser, Bernd Dworniczak, Christoph Engel, Alfons Meindl, Rita K. Schmutzler, Eric Hahnen   +44 more
doaj   +2 more sources

Hereditary breast and ovarian cancer (HBOC): review of its molecular characteristics, screening, treatment, and prognosis

Breast Cancer, 2020
Breast cancer is a common cancer affecting a large number of patients. Notably, 5–10% of all breast cancer patients are genetically predisposed to cancers.
Reiko Yoshida
exaly   +2 more sources

EMQN best practice guidelines for genetic testing in hereditary breast and ovarian cancer. [PDF]

Eur J Hum Genet
Hereditary Breast and Ovarian Cancer (HBOC) is a genetic condition associated with increased risk of cancers. The past decade has brought about significant changes to hereditary breast and ovarian cancer (HBOC) diagnostic testing with new treatments ...
McDevitt T, Durkie M, Arnold N, Burghel GJ, Butler S, Claes KBM, Logan P, Robinson R, Sheils K, Wolstenholme N, Hanson H, Turnbull C, Hume S.   +12 more
europepmc   +2 more sources

Role of MRE11 in DNA damage repair pathway dynamics and its diagnostic and prognostic significance in hereditary breast and ovarian cancer [PDF]

BMC Cancer
Background DNA damage repair pathway genes are key components for maintaining genomic stability and are mainly associated with hereditary breast and ovarian cancer.
Bhoomi Tarapara, Franky Shah
doaj   +2 more sources

The risk of endocrine interventions in carriers of a genetic predisposition for breast and gynecologic cancers: recommendations of the German Consortium for Hereditary Breast and Ovarian Cancer. [PDF]

J Cancer Res Clin Oncol
To support doctors in counselling women with genetic predisposition for breast or gynecologic cancers on endocrine interventions. Evidence on the safety of endocrine interventions for fertility treatment, contraception, hormone replacement therapy after ...
Ortmann O, Schüler-Toprak S, Kast K, working group “Hormones”, The German Consortium for Hereditary Breast, Ovarian Cancer (GC-HBOC).   +5 more
europepmc   +2 more sources

HerediVar and HerediClassify: tools for streamlining genetic variant classification in hereditary breast and ovarian cancer [PDF]

Human Genomics
Background Multiple different evidence types as well as gene-specific variant classification guidelines need to be considered during the classification of variants, making the process complex.
Anna-Lena Katzke, Marvin Doebel, Jan Hauke, Gunnar Schmidt, Marc Sturm   +4 more
doaj   +2 more sources

Psychological factors and the uptake of preventative measures in BRCA1/2 pathogenic variant carriers: results of a prospective cohort study

Hereditary Cancer in Clinical Practice, 2022
Background Women carrying BRCA1/2 pathogenic variants are exposed to elevated risks of developing breast cancer (BC) and are faced by a complex decision-making process on preventative measures, i.e., risk-reducing mastectomy (RRM), and intensified breast
Julia Dick, Anja Tüchler, Anne Brédart, Frank Vitinius, Kirsten Wassermann, Kerstin Rhiem, Rita K. Schmutzler   +6 more
doaj   +1 more source

Predictors of cardiopulmonary fitness in cancer-affected and -unaffected women with a pathogenic germline variant in the genes BRCA1/2 (LIBRE-1)

Scientific Reports, 2022
Physical activity (PA) helps prevention and aftercare of sporadic breast cancer (BC), cardiopulmonary fitness (CPF) being an age-independent predictor of tumor-specific mortality.
A. Berling-Ernst, M. Yahiaoui-Doktor, M. Kiechle, C. Engel, J. Lammert, S. Grill, R. Dukatz, K. Rhiem, F. T. Baumann, S. C. Bischoff, N. Erickson, T. Schmidt, U. Niederberger, M. Siniatchkin, M. Halle   +14 more
doaj   +1 more source